262 related articles for article (PubMed ID: 11161972)
1. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
2. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
3. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.
Cole MS; Anasetti C; Tso JY
J Immunol; 1997 Oct; 159(7):3613-21. PubMed ID: 9317161
[TBL] [Abstract][Full Text] [Related]
4. Localization of an Fc-binding reactivity to the constant region of human IgG4. Implications for the pathogenesis of rheumatoid arthritis.
Zack DJ; Stempniak M; Wong AL; Weisbart RH
J Immunol; 1995 Nov; 155(10):5057-63. PubMed ID: 7594514
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates.
Fishwild DM; Hudson DV; Deshpande U; Kung AH
Clin Immunol; 1999 Aug; 92(2):138-52. PubMed ID: 10444358
[TBL] [Abstract][Full Text] [Related]
6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
7. Site-directed in vitro immunization leads to a complete human monoclonal IgG4 lambda that binds specifically to the CDR2 region of CTLA-4 (CD152) without interfering the engagement of natural ligands.
Chin LT; Chu C; Chen HM; Hsu SC; Weng BC; Chu CH
BMC Biotechnol; 2007 Aug; 7():51. PubMed ID: 17714596
[TBL] [Abstract][Full Text] [Related]
8. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
[TBL] [Abstract][Full Text] [Related]
9. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
Mason U; Aldrich J; Breedveld F; Davis CB; Elliott M; Jackson M; Jorgensen C; Keystone E; Levy R; Tesser J; Totoritis M; Truneh A; Weisman M; Wiesenhutter C; Yocum D; Zhu J
J Rheumatol; 2002 Feb; 29(2):220-9. PubMed ID: 11838838
[TBL] [Abstract][Full Text] [Related]
10. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Zuckier LS; Chang CJ; Scharff MD; Morrison SL
Cancer Res; 1998 Sep; 58(17):3905-8. PubMed ID: 9731501
[TBL] [Abstract][Full Text] [Related]
11. Intrachain disulfide bond in the core hinge region of human IgG4.
Bloom JW; Madanat MS; Marriott D; Wong T; Chan SY
Protein Sci; 1997 Feb; 6(2):407-15. PubMed ID: 9041643
[TBL] [Abstract][Full Text] [Related]
12. Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function.
Isaacs JD; Greenwood J; Waldmann H
J Immunol; 1998 Oct; 161(8):3862-9. PubMed ID: 9780151
[TBL] [Abstract][Full Text] [Related]
13. Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer.
Rispens T; Meesters J; den Bleker TH; Ooijevaar-De Heer P; Schuurman J; Parren PW; Labrijn A; Aalberse RC
Mol Immunol; 2013 Jan; 53(1-2):35-42. PubMed ID: 22784992
[TBL] [Abstract][Full Text] [Related]
14. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of pigs with low doses of monoclonal antibodies against porcine CD4 and CD8 antigens.
Lohse L; Nielsen J; Eriksen L
APMIS; 2006 Jan; 114(1):23-31. PubMed ID: 16499657
[TBL] [Abstract][Full Text] [Related]
16. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
17. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
18. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin.
Ward RH; Capon DJ; Jett CM; Murthy KK; Mordenti J; Lucas C; Frie SW; Prince AM; Green JD; Eichberg JW
Nature; 1991 Aug; 352(6334):434-6. PubMed ID: 1907354
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
Yocum DE; Solinger AM; Tesser J; Gluck O; Cornett M; O'Sullivan F; Nordensson K; Dallaire B; Shen CD; Lipani J
J Rheumatol; 1998 Jul; 25(7):1257-62. PubMed ID: 9676753
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas.
Troadec S; Chentouf M; Cérutti M; Nguyen B; Olive D; Bès C; Chardès T
J Immunother; 2007; 30(2):190-202. PubMed ID: 17471166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
